Literature DB >> 32644194

Public-private partnership: strategies for continuing urgent elective operative care during the COVID-19 pandemic.

J C Bolger1, M E Kelly1, C Whelan2, A Doyle2, H Frizelle3, W D Boyd4,5, G P McEntee1,6, J B Conneely1,6.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32644194      PMCID: PMC7361733          DOI: 10.1002/bjs.11774

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


× No keyword cloud information.
Editor Novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the coronavirus disease (COVID-19) have had an enormous impact on non-COVID-19 related care. A particular challenge is maintaining high-quality surgical care for patients requiring urgent operations. The impact of COVD-19 on perioperative outcomes is unclear, although there may be increased perioperative mortality. Recommendations from surgical societies are conflicting, but many recommend postponing surgery when possible and pursuing non-surgical alternatives[1,5]. There is clear justification for this: reducing demand on bed capacity, the anaesthetic workforce and a reduction in demand for critical care resources. It is unclear whether deferring surgery for tumours with rapid doubling times, or with aggressive biology will result in an increase in cancer-related deaths. Establishing a safe pathway for access to urgent surgical care is imperative in the COVID-19 era. In Ireland, as part of the government's response to the COVID-19 pandemic, the state has temporarily leased the private hospital system. This has dramatically increased bed capacity, critical care access and operating theatre space. It has facilitated a rapid re-alignment of the surgical services to attempt to allow safe and timely urgent surgical care. Our co-located private hospital is a 205-bed institution with eight operating theatres and full critical care capacity. Prior to the nationwide leasing of private hospital capacity, the decision was made to designate it as a COVID-19 free hospital. All COVID-19 related care is centralized to the public hospital, including patients who developed COVID-19 complications in the perioperative period. The cornerstones of our practice to date have been: 1. Separate hospitals for COVID-19 and non-COVID-19 related care; 2. Separation of surgical teams, to COVID-19 and non-COVID-19 related care; 3. Screening questionnaires with targeted testing; 4. Immediate transfer of COVID-19 related morbidity to the COVID-19 designated hospital; 5. PPE with a minimum of FFP2 masks, face shields, full gown and gloves for all staff in theatre complex; 6. Minimizing the number of staff present in theatre. Screening questions are designed to highlight patients at a high risk of having COVID-19, either though symptoms, behaviours or contacts. There is an additional risk assessment prior to induction of anaesthesia. In the first 4 weeks of this protocol, 185 patients successfully underwent urgent operations. The cases, broken down by treating specialty with length of stay data and COVID-19 related morbidity is outlined in . One hundred and ninety eight patients were screened prior to admission. Thirteen patients had their surgery deferred. These were due to cough (n = 7), close contact (n = 5) and fever (n = 1). One patient developed COVID-19 related symptoms post-operatively and was transferred to the public hospital for further care.
SpecialtyDay casesInpatient casesMedian length of stay for inpatients (range)COVID-19 related morbidity
General surgery40302 (1-8)0
Gynaecology13233 (1-7)0
Cardiothoracic surgery2910 (6-11)1
Ophthalmology80n/a0
Plastic surgery200n/a0
Otolaryngology20n/a0
Orthopaedic surgery0130
Urological surgery18172 (1-5)0
Vascular surgery024/50
The pandemic is likely to continue for many months. It is vital that we continue to offer a high level of care for surgical patients. Where feasible, elective cases should be performed in a COVID-19 free institution, with rapid inter-institution transfer of patients if patients develop COVID-like symptoms. Robust contact tracing of staff members is necessary, and judicious use of PPE is essential. As there is still no robust data on the safety of open or minimally invasive surgery without PPE in the COVID-19 era, we are currently recommending full PPE for our theatre staff, to protect both patients and healthcare workers. Although challenging, the COVID-19 pandemic offers an opportunity to reflect on current practices. Lateral thinking will be required as we devise new pathways to ensure the provision of high-quality surgical care in the COVID-19 era and this public-private partnership is one example of how this can be achieved. The authors declare no conflict of interest.
  4 in total

Review 1.  Health, Economic and Social Development Challenges of the COVID-19 Pandemic: Strategies for Multiple and Interconnected Issues.

Authors:  Sigamani Panneer; Komali Kantamaneni; Udhayakumar Palaniswamy; Lekha Bhat; Robert Ramesh Babu Pushparaj; Kesavan Rajasekharan Nayar; Hilaria Soundari Manuel; F X Lovelina Little Flower; Louis Rice
Journal:  Healthcare (Basel)       Date:  2022-04-21

2.  Successful maintenance of process and outcomes for oesophageal cancer surgery in Ireland during the first wave of the COVID-19 pandemic.

Authors:  Jarlath C Bolger; Noel E Donlon; Waqas Butt; Colm Neary; Mohammed Al Azzawi; Orla Brett; Sinead King; Eithne Downey; Mayilone Arumugasamy; Thomas Murphy; William B Robb; Chris G Collins; Paul A Carroll; Claire L Donohoe; Narayanasamy Ravi; John V Reynolds
Journal:  Ir J Med Sci       Date:  2021-03-16       Impact factor: 2.089

Review 3.  Patient, Surgeon, and Health Care Worker Safety during the COVID-19 Pandemic.

Authors:  Arnulf H Hölscher
Journal:  Ann Surg       Date:  2021-11-01       Impact factor: 13.787

4.  Using a Combined Lean and Person-Centred Approach to Support the Resumption of Routine Hospital Activity following the First Wave of COVID-19.

Authors:  Ailish Daly; Sean Paul Teeling; Suzanne Garvey; Marie Ward; Martin McNamara
Journal:  Int J Environ Res Public Health       Date:  2022-02-27       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.